| 1730 |
National Cancer Institute |
Html |
en |
Blood-Forming Stem Cell Transplants |
A fact sheet that explains the step-by-step procedures of two types of transplantations used with high-dose chemotherapy, including their risks and benefits. |
| red blood cells | 0.400014 |
| cancer treatment | 0.26536 |
| cord blood | 0.408194 |
| public cord blood | 0.298389 |
| bone marrow cells | 0.392639 |
| cord blood bank | 0.313292 |
| embryonic stem cells | 0.414015 |
| cord stem cells | 0.382315 |
| healthy cells | 0.309763 |
| bone marrow donation | 0.293131 |
| white blood cells | 0.53145 |
| transplanted stem cells | 0.39836 |
| HLA-matched stem cells | 0.374986 |
| clinical trials | 0.346744 |
| healthy stem cells | 0.372316 |
| stem cells | 0.95315 |
| stem cell transplant | 0.291072 |
| multiple myeloma | 0.26697 |
| Bone marrow aspiration | 0.292859 |
| cord blood banks | 0.343333 |
| immature cells | 0.319355 |
| HLA antigens | 0.259199 |
| appropriate unrelated donor | 0.262231 |
| radiation therapy | 0.329306 |
| transplantation | 0.292216 |
|
| blood-forming stem cells | 0.415789 |
| immature nerve cells | 0.328089 |
| Large volunteer donor | 0.262362 |
| new blood cells | 0.334223 |
| blood stem cell | 0.339528 |
| cancer cells | 0.404042 |
| special blood test | 0.260646 |
| peripheral blood stem | 0.362146 |
| anticancer drugs | 0.263549 |
| donor | 0.356002 |
| PBSCT | 0.299118 |
| patient | 0.341681 |
| marrow’s ability | 0.258871 |
| blood stem cells | 0.413585 |
| healthy bone marrow | 0.302284 |
| umbilical cord blood | 0.366965 |
| umbilical cord | 0.389737 |
| harvested cells | 0.30119 |
| commercial cord blood | 0.270418 |
| Marrow Donor Program® | 0.288844 |
| BMT | 0.322432 |
| bone marrow | 0.850438 |
| autologous transplant | 0.272369 |
| hematopoietic stem cells | 0.478378 |
|
CLICK HERE |
| 1734 |
National Cancer Institute |
Html |
en |
Diethylstilbestrol (DES) and Cancer |
A fact sheet about DES (a synthetic form of estrogen) and the health problems of children who were exposed to DES while in the womb. |
| DES grandsons | 0.538814 |
| Hatch EE | 0.382563 |
| DES exposure | 0.67711 |
| Cell Cancer Registry | 0.421337 |
| pregnant women | 0.436903 |
| mothers | 0.380607 |
| Pap test | 0.370345 |
| researchers | 0.371735 |
| pregnancy | 0.387046 |
| slightly increased risk | 0.395077 |
| DES Follow-up Study | 0.632841 |
| DES-exposed women | 0.392223 |
| health problems | 0.418784 |
| slightly higher risk | 0.374572 |
| prenatal DES exposure | 0.579068 |
| hormone replacement therapy | 0.402773 |
| possible health effects | 0.424124 |
| health effects | 0.485372 |
| women | 0.613207 |
| DES daughters | 0.874038 |
| abnormal cells | 0.390363 |
| overall cancer risk | 0.3987 |
| prenatally exposed men | 0.392794 |
| regular breast cancer | 0.374945 |
|
| Hormonal Transplacental Carcinogenesis | 0.419307 |
| third-generation daughters | 0.375828 |
| DES-exposed daughters | 0.446699 |
| adverse health effects | 0.420665 |
| clear cell adenocarcinoma | 0.541335 |
| unexposed women | 0.492521 |
| DES granddaughters | 0.631672 |
| studies | 0.380945 |
| National Cancer Institute | 0.372742 |
| Military medical records | 0.370524 |
| higher risk | 0.376562 |
| breast cancer risk | 0.433356 |
| breast cancer | 0.508269 |
| birth defects | 0.404912 |
| cervical intraepithelial neoplasia | 0.371506 |
| DES-exposed mothers | 0.370151 |
| DES | 0.962997 |
| squamous intraepithelial lesions | 0.371888 |
| abnormal cell changes | 0.370094 |
| Clear Cell Cancer | 0.418711 |
| et al | 0.459666 |
| New England Journal | 0.400964 |
| cancer | 0.517317 |
| risk | 0.491261 |
|
CLICK HERE |
| 1849 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de próstata (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de próstata. |
| Compton CC | 0.32822 |
| preoperative nomogram | 0.351745 |
| outcome after | 0.326979 |
| progression after psa | 0.331315 |
| Albertsen PC | 0.319652 |
| prostate specific | 0.36016 |
| clinically localized | 0.351298 |
| Kabalin JN | 0.319448 |
| American Cancer Society | 0.354812 |
| Radical prostatectomy versus | 0.362604 |
| Eastham JA | 0.338512 |
| versus watchful waiting | 0.321163 |
| following radical prostatectomy | 0.340792 |
| PSA anormal | 0.32618 |
| 7th ed | 0.328183 |
| Radiat Oncol Biol | 0.401027 |
| Estados Unidos | 0.34545 |
| Natl Cancer Inst | 0.962766 |
| cancer staging | 0.41957 |
| men with | 0.323828 |
| Stamey TA | 0.333393 |
| Radical prostatectomy treated | 0.32026 |
| Union Against Cancer | 0.327902 |
| versus gleason | 0.324714 |
| prostate biopsy | 0.325976 |
|
| with psa testing | 0.327026 |
| ecografÃa transrectal | 0.331137 |
| prostate with radiotherapy | 0.319235 |
| Cancer Facts | 0.330577 |
| gammagrafÃa ósea | 0.32132 |
| radical prostatectomy | 0.783813 |
| after radical prostatectomy | 0.482799 |
| Cancer Staging Manual | 0.40851 |
| recurrence after | 0.340439 |
| New York | 0.323092 |
| Clin Oncol | 0.387513 |
| predict pathological stage | 0.323561 |
| Oncol Biol Phys | 0.404255 |
| Oncology Consensus Panel | 0.323099 |
| Kattan MW | 0.336259 |
| systematic review | 0.320343 |
| with clinically localized | 0.323887 |
| Byrd DR | 0.326227 |
| American Joint Committee | 0.318729 |
| Partin AW | 0.341859 |
| transrectal ultrasound guided | 0.325554 |
| AJCC Cancer Staging | 0.413497 |
| Edge SB | 0.328269 |
| PSA following | 0.325762 |
|
CLICK HERE |
| 1939 |
National Cancer Institute |
Html |
es |
Adaptación al cáncer: ansiedad y sufrimiento (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las difíciles respuestas emocionales que se presentan en muchos de los pacientes con cáncer. Este sumario se enfoca en asuntos de la adaptación normal, alteración psicosocial y trastornos de adaptación. |
| La espiritualidad | 0.829227 |
| siguientes aspectos | 0.951689 |
| intensa ansiedad | 0.886965 |
| siguientes tipos | 0.835996 |
| largo plazo | 0.911949 |
| ¿Qué efectos | 0.840354 |
| siguientes perÃodos | 0.85698 |
| siguientes sÃntomas | 0.824791 |
| siguientes riesgos | 0.776419 |
| Visuals Online | 0.784027 |
| Physician Data | 0.774429 |
| siguientes problemas | 0.817253 |
|
| siguientes factores | 0.894404 |
| Mucha transpiración | 0.807275 |
| resultados correctos | 0.846693 |
| libre uso | 0.789 |
| siguientes situaciones | 0.941031 |
| Data Query | 0.774207 |
| siguientes caracterÃsticas | 0.904197 |
| Cancer Institute | 0.786402 |
| página manejo | 0.784108 |
| suficiente dinero | 0.80221 |
| siguientes sumarios | 0.945414 |
| usa compulsiones | 0.805006 |
|
CLICK HERE |
| 1981 |
National Cancer Institute |
Html |
es |
Etapa final de la vida (PDQ®)–Versión para pacientes |
Sumario informativo revisado por expertos sobre el tratamiento y la atención del paciente de cáncer desde los últimos días hasta las últimas horas de vida; esto incluye los síntomas comunes, los dilemas éticos que pueden surgir y la función que desempeña el oncólogo en proveer cuidados al paciente y su familia durante este período. |
| etapa final | 0.952722 |
| alientoLa sensación | 0.303004 |
| siguientes afecciones | 0.302215 |
| Mejor comunicación | 0.301527 |
| posibles daños | 0.30146 |
| Contracciones mioclónicasLas | 0.30427 |
| siguientes tipos | 0.302214 |
| PDQ Aflicción | 0.302895 |
| PDQ Etapa final | 0.30437 |
| suficiente oxÃgeno | 0.302526 |
| HemorragiaLa hemorragia | 0.303897 |
| vÃa rectal | 0.302425 |
| obstructiva crónica | 0.302498 |
| posibles riesgos | 0.304519 |
| efectos directos | 0.302483 |
| vÃas respiratorias | 0.375323 |
| muerteEl estertor | 0.304331 |
| National Cancer Institute | 0.30139 |
| especial cánceres | 0.30221 |
| Mejor alivio | 0.301759 |
| próximas horas | 0.302343 |
|
| Instituto Nacional | 0.302514 |
| PDQ Planificar | 0.312661 |
| contracciones súbitas | 0.303377 |
| pequeñas cantidades | 0.302149 |
| importantes beneficios | 0.301883 |
| cuánta probabilidad | 0.301726 |
| Physician Data Query | 0.305159 |
| LÃquidosLos pacientes | 0.308282 |
| PDQ Fatiga | 0.306846 |
| FatigaLa fatiga | 0.303104 |
| PDQ Delirium | 0.307935 |
| término instrucciones | 0.301507 |
| posibles beneficios | 0.301551 |
| nutrición parenteral | 0.304251 |
| reanimación cardiorrespiratoria | 0.301653 |
| causa sufrimiento | 0.302836 |
| Mejor perspectiva | 0.301742 |
| sufrimiento extremo | 0.306751 |
| numerosos cambios | 0.308661 |
| ReanimaciónLos pacientes | 0.308108 |
|
CLICK HERE |
| 15480 |
National Cancer Institute |
Html |
en |
Grantees or Grant Applicants Submitting Data |
In order to be compliant with the Genomic Data Sharing (GDS) Policy, extramural investigators should use the following to guide their steps through the grant life-cycle process. |
| annual Progress Report | 0.62504 |
| data | 0.849889 |
| Institutional Certification | 0.882661 |
| similar manner | 0.478201 |
| accession number | 0.48592 |
| section | 0.333306 |
| PO/PD | 0.491096 |
| Assignment | 0.33161 |
| approved DSP | 0.538409 |
| extramural investigators | 0.782153 |
| 1. Plan Project | 0.689974 |
| Basic Study Information | 0.674507 |
| grant funding | 0.568662 |
| confirmation | 0.333875 |
| steps | 0.331094 |
| ARA | 0.342301 |
| submission portal | 0.610861 |
| plans | 0.336284 |
| grant application | 0.941037 |
| receipt | 0.33802 |
| GDS policy | 0.525866 |
| Upload Data | 0.545134 |
| dbGaP staff | 0.485771 |
| data certification process | 0.735794 |
| program officer/program director | 0.674634 |
|
| grants process | 0.480049 |
| grant life-cycle process | 0.816123 |
| Basic Information form | 0.63633 |
| dbGaP Study Release | 0.648367 |
| DSPs | 0.34954 |
| initiation | 0.332734 |
| pre-award process | 0.509608 |
| submission process | 0.502601 |
| required fields | 0.479311 |
| expectations | 0.381962 |
| place | 0.332574 |
| 3. | 0.332387 |
| cleaning | 0.332176 |
| data submission formats | 0.780089 |
| study submission information | 0.687432 |
| Resource Sharing Plan | 0.663305 |
| QA/QC Data Submission | 0.730259 |
| Information form | 0.651102 |
| Submit Just-in-Time Materials | 0.722172 |
| Data Generation Completed | 0.715899 |
| GPA | 0.642745 |
| quality assurance check | 0.641113 |
| Write Grant Application | 0.78666 |
| data upload | 0.531576 |
|
CLICK HERE |
| 16562 |
National Cancer Institute |
Html |
en |
Screen to Save: NCI Colorectal Cancer Outreach and Screening Initiative |
NCI Colorectal Cancer Outreach and Screening Initiative aims to increase colorectal cancer screening rates among ethnically and racially diverse and rural communities nationwide.
|
| NCI-designated Cancer Centers | 0.680452 |
| country | 0.523395 |
| evidence-based resources | 0.584437 |
| education | 0.537172 |
| National Cancer Advisory | 0.70446 |
| Alaskan Natives | 0.584304 |
| recommendations | 0.526636 |
| overall assessment | 0.573123 |
| ethnically diverse communities | 0.720461 |
| local communities | 0.586899 |
| colorectal screening rates | 0.853048 |
| outreach activities | 0.578711 |
| colorectal cancer screening | 0.850894 |
| rural areas | 0.584762 |
| colorectal cancer | 0.992617 |
| Cancer Control National | 0.675464 |
| PACHE-funded community health | 0.657281 |
| community levels | 0.588626 |
| National Outreach Network | 0.661026 |
| Health Disparities Program | 0.668335 |
| women age | 0.582977 |
| Reduce Cancer Health | 0.704459 |
| American Indians | 0.579831 |
| Colorectal Cancer Awareness | 0.761387 |
|
| Cancer Moonshot | 0.620655 |
| Cancer Health Disparities | 0.821429 |
| NCI Center | 0.608436 |
| Blacks/African Americans | 0.579578 |
| Save initiative | 0.611204 |
| Cancer Health Equity | 0.685373 |
| NCI Colorectal Cancer | 0.830393 |
| Regional Coordinating Directors | 0.639583 |
| diverse partner network | 0.664475 |
| Blue Ribbon Panel | 0.662084 |
| rural communities | 0.646304 |
| Geographic Management | 0.573805 |
| community health educators | 0.957975 |
| outreach efforts | 0.576306 |
| Native Hawaiians | 0.58859 |
| screening resources | 0.639461 |
| Pacific Islanders | 0.584476 |
| evidence-based colorectal cancer | 0.788139 |
| key role | 0.575779 |
| colorectal screening behaviors | 0.792179 |
| NCI-approved colorectal cancer | 0.776303 |
| additional community engagements | 0.645113 |
| Screening Initiative | 0.658551 |
| information | 0.537846 |
|
CLICK HERE |
| 16713 |
National Cancer Institute |
Html |
es |
Iniciativa de Respuestas Excepcionales: Preguntas y respuestas |
El Instituto Nacional del Cáncer (NCI) emprendió la Iniciativa de Respuestas Excepcionales a fin de entender la base molecular de los tumores en pacientes de cáncer que responden en forma excepcional al tratamiento, principalmente quimioterapia. |
| Exceptional Responders | 0.786989 |
| suficiente información | 0.61563 |
| Sequencing Identifies | 0.586522 |
| poderosa técnica | 0.577603 |
| tejido no puede usarse para otras | 0.723672 |
| siguientes criterios | 0.611344 |
| llamado data access request | 0.624892 |
| ARN mensajero | 0.581431 |
| Everolimus Sensitivity | 0.593577 |
| suficiente ácido | 0.633822 |
| Genome Sequencing | 0.743091 |
| suficiente tejido | 0.888254 |
| genes tsc1 | 0.601267 |
| datos dbGAP | 0.580415 |
| estudio piloto | 0.664379 |
| tejido fijo en formol | 0.691726 |
| Exceptional Responders Data | 0.636284 |
|
| Exceptional Responders Initiative | 0.702067 |
| consentimiento apropiado para investigaciones | 0.678722 |
| fármacos similares. El estudio | 0.741131 |
| Instituto Nacional | 0.57833 |
| gen tsc1 | 0.738554 |
| Trials Support Unit | 0.638511 |
| descubrimientos prometedores | 0.585883 |
| datos clÃnicos a medidata | 0.649717 |
| Revisión Central de Adultos | 0.624848 |
| extensa experiencia | 0.580712 |
| requiere varios pasos | 0.583341 |
| pacientes con respuestas | 0.618767 |
| centro biospecimen core | 0.880872 |
| tumores sólidos | 0.758056 |
| enfermedad y el | 0.583796 |
| aun pacientes | 0.751408 |
|
CLICK HERE |
| 17189 |
National Cancer Institute |
Html |
en |
Sexual Health Issues in Women with Cancer |
Cancer treatments such as chemotherapy, hormone therapy, and radiation may cause sexual problems in women. Conditions may include vaginal dryness, vaginal stenosis, and vaginal atrophy. Learn how to manage and treat these sexual problems. |
| cancer treatment | 0.51645 |
| vaginal tissue | 0.532819 |
| primary ovarian insufficiency | 0.548774 |
| endocrine therapy | 0.478386 |
| health care team | 0.776749 |
| sexual life | 0.612375 |
| support group | 0.540233 |
| gynecologic cancers | 0.477639 |
| social worker | 0.530013 |
| pelvic muscles | 0.474973 |
| sexual activity | 0.559668 |
| sexual health | 0.668647 |
| sexual intercourse | 0.555683 |
| low estrogen levels | 0.65848 |
| hair loss | 0.473268 |
| physical changes | 0.478751 |
| birth control | 0.564552 |
| Fertility Issues | 0.55759 |
| effects | 0.479305 |
| sexual problems | 0.5327 |
| hot flashes | 0.548172 |
| radiation therapy | 0.542011 |
| long term | 0.480571 |
| valuable suggestions | 0.473342 |
| vaginal dryness | 0.649951 |
|
| vaginal gels | 0.527917 |
| problems | 0.541005 |
| women | 0.505517 |
| cancer treatments | 0.472282 |
| treatment | 0.973526 |
| sex life | 0.471664 |
| personal health factors | 0.547006 |
| vaginal secretions | 0.525892 |
| cancer-related support services | 0.536181 |
| changes | 0.511207 |
| Vaginal stenosis | 0.532538 |
| vaginal wall | 0.531486 |
| vaginal atrophy | 0.531565 |
| hormone therapy | 0.536753 |
| sexual changes | 0.501579 |
| bladder retention | 0.472634 |
| shorter vagina | 0.48061 |
| sexual health expert | 0.553722 |
| support groups | 0.47572 |
| Breast Cancer | 0.475837 |
| doctor | 0.494029 |
| bowel function | 0.475187 |
| national organizations | 0.470856 |
| time | 0.509374 |
|
CLICK HERE |
| 17222 |
National Cancer Institute |
Html |
en |
Tumor DNA Sequencing in Cancer Treatment |
Tumor DNA sequencing (also called genetic profiling or genetic testing) is a test to identify DNA changes in a patient’s cancer. In some cases, this information can help determine a treatment plan. |
| unique DNA changes | 0.327494 |
| health care provider | 0.21495 |
| lung tumor | 0.253938 |
| tumor sequencing | 0.343527 |
| specific genetic alterations | 0.302101 |
| healthy cells | 0.230873 |
| Multigene panel tests | 0.208409 |
| health care team | 0.2107 |
| frequently used sequencing | 0.320207 |
| hereditary cancer syndromes | 0.221971 |
| health care providers | 0.211937 |
| whole-genome sequencing | 0.314537 |
| cancer types | 0.228448 |
| DNA changes | 0.331071 |
| patient care | 0.205253 |
| targeted sequencing tests | 0.342426 |
| broad tumor DNA | 0.375946 |
| heterogeneous tumor | 0.233471 |
| DNA sequencing tests | 0.507176 |
| precision medicine | 0.222532 |
| single cancer type | 0.228039 |
| lung cancer cells | 0.3596 |
| treatment | 0.286045 |
| precision medicine trials | 0.205063 |
|
| DNA alteration | 0.251455 |
| NCI-COG Pediatric MATCH | 0.207207 |
| inherited genetic alteration | 0.228682 |
| DNA sequence | 0.253453 |
| cancer cells | 0.454035 |
| unique genetic alterations | 0.280668 |
| sequencing tests cost | 0.308627 |
| EGFR mutation | 0.209321 |
| Broad DNA sequencing | 0.411749 |
| cancer-causing DNA changes | 0.297683 |
| way cells function | 0.250384 |
| tumor dna | 0.91525 |
| tumor dna sequencing | 0.748819 |
| DNAÂ sequencer | 0.254089 |
| Clinical tumor DNA | 0.406068 |
| health care | 0.275099 |
| DNA sequencing test | 0.405098 |
| mRNA expression test | 0.209986 |
| breast cancer | 0.203535 |
| genetic alterations | 0.703142 |
| cancer | 0.512553 |
| standard treatment | 0.204466 |
| whole-exome sequencing | 0.314247 |
| quantitative mRNA test | 0.208612 |
|
CLICK HERE |